Table 4. Comparison of deranged inflammatory score and overall survival in patients receiving and declined chemotherapy in the validation set.
|
Median survival (months) |
|
||
|---|---|---|---|
| Inflammation-based system | Chemotherapy (95% CI) | No chemotherapy (95% CI) | P-value |
| NLR <5 (N=72) | 21.2 (14.8–27.4) | 7.0 (3.9–10.1) | <0.01 |
| NLR >5 (N=117) |
10.2 (5.9–14.5) |
3.5 (1.0–6.0) |
|
| mGPS 0 (N=42) | 23.3 (11.7–35.3) | 4.6 (3.1–6.0) | <0.01 |
| mGPS 1 (N=53) | 12.8 (4.5–21.1) | 2.1 (0.7–3.4) | |
| mGPS 2 (N=19) | 2.9 (2.1–3.8) | 0.4 (0.1–0.6) | |
Abbreviations: CI=confidence interval; mGPS=modified Glasgow Prognostic Score; NLR=neutrophillymphocyte ratio. Associations reaching statistical significance (P<0.05) are highlighted in bold.